PERSEUS PROTEOMICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 311 JPY | -6.04% |
|
-7.44% | -49.68% |
Valuation
| Fiscal Period: March | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 4,892 | 3,504 |
| Enterprise Value (EV) 1 | 1,678 | 1,060 |
| P/E ratio | -7.64 x | -4.46 x |
| Yield | - | - |
| Capitalization / Revenue | 68.9 x | 37.3 x |
| EV / Revenue | 23.6 x | 11.3 x |
| EV / EBITDA | -3,562,442 x | -1,532,207 x |
| EV / FCF | -6,721,724 x | -1,678,666 x |
| FCF Yield | -0% | -0% |
| Price to Book | 1.55 x | 1.46 x |
| Nbr of stocks (in thousands) | 11,759 | 11,759 |
| Reference price 2 | 416.0 | 298.0 |
| Announcement Date | 6/23/22 | 6/23/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 303 | 275 | 85 | 67 | 71 | 94 |
| EBITDA | - | - | - | - | -471 | -692 |
| EBIT 1 | -166 | -145 | -812 | -411 | -473 | -697 |
| Operating Margin | -54.79% | -52.73% | -955.29% | -613.43% | -666.2% | -741.49% |
| Earnings before Tax (EBT) 1 | -177 | -162 | -840 | -412 | -598 | -785 |
| Net income 1 | -178 | -163 | -841 | -413 | -599 | -786 |
| Net margin | -58.75% | -59.27% | -989.41% | -616.42% | -843.66% | -836.17% |
| EPS 2 | -68.97 | -26.52 | -136.8 | -59.00 | -54.47 | -66.84 |
| Free Cash Flow | - | - | - | - | -249.6 | -631.6 |
| FCF margin | - | - | - | - | -351.58% | -671.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/17/20 | 2/17/20 | 5/19/21 | 5/19/21 | 6/23/22 | 6/23/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,449 | 1,100 | 482 | 1,069 | 3,214 | 2,444 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | -250 | -632 |
| ROE (net income / shareholders' equity) | - | -11.6% | -92.8% | -52.7% | -28.3% | -28.3% |
| ROA (Net income/ Total Assets) | - | -6.31% | -53.2% | -30.9% | -13.4% | -14.9% |
| Assets 1 | - | 2,585 | 1,580 | 1,338 | 4,476 | 5,292 |
| Book Value Per Share 2 | 577.0 | 216.0 | 78.90 | 130.0 | 268.0 | 204.0 |
| Cash Flow per Share 2 | 561.0 | 179.0 | 78.40 | 128.0 | 274.0 | 208.0 |
| Capex | - | - | - | - | 33 | 164 |
| Capex / Sales | - | - | - | - | 46.48% | 174.47% |
| Announcement Date | 2/17/20 | 2/17/20 | 5/19/21 | 5/19/21 | 6/23/22 | 6/23/23 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -49.68% | 26.35M | |
| +0.10% | 91.42B | |
| +2.76% | 41.08B | |
| -9.06% | 34.26B | |
| +54.69% | 25.27B | |
| -9.14% | 12.81B | |
| -12.11% | 11.6B | |
| -43.61% | 11.42B | |
| +6.37% | 9.16B | |
| -6.90% | 8.22B |
- Stock Market
- Equities
- 4882 Stock
- Financials Perseus Proteomics Inc.
